Fingerprint
Dive into the research topics of 'A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
A. Pardanani, A. Tefferi, C. Jamieson, N. Gabrail, C. Lebedinsky, G. Gao, F. Liu, C. Xu, H. Cao, M. Talpaz
Research output: Contribution to journal › Article › peer-review
51
Scopus
citations